MX2015013470A - Microcapsulas de piperaquina y composiciones que las contienen. - Google Patents

Microcapsulas de piperaquina y composiciones que las contienen.

Info

Publication number
MX2015013470A
MX2015013470A MX2015013470A MX2015013470A MX2015013470A MX 2015013470 A MX2015013470 A MX 2015013470A MX 2015013470 A MX2015013470 A MX 2015013470A MX 2015013470 A MX2015013470 A MX 2015013470A MX 2015013470 A MX2015013470 A MX 2015013470A
Authority
MX
Mexico
Prior art keywords
compositions containing
microcapsule
drug
pharmaceutical composition
core
Prior art date
Application number
MX2015013470A
Other languages
English (en)
Other versions
MX354453B (es
Inventor
Flavio Fabiani
Luigi Boltri
Christian Stollberg
Giancarla Bianchi
Original Assignee
Adare Pharmaceuticals S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adare Pharmaceuticals S R L filed Critical Adare Pharmaceuticals S R L
Publication of MX2015013470A publication Critical patent/MX2015013470A/es
Publication of MX354453B publication Critical patent/MX354453B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)

Abstract

La presente invención provee una composición farmacéutica de microcápsula de por lo menos un fármaco de bisquinolina; dicha microcápsula comprende un núcleo de fármaco de una cantidad farmacéuticamente efectiva de un fármaco de bisquinolina y un recubrimiento polimérico sobre el núcleo; esta composición farmacéutica de microcápsula tiene propiedades farmacéuticas deseables, que incluyen efecto enmascarador de sabor y una alta estabilidad.
MX2015013470A 2013-03-22 2014-03-21 Microcapsulas de piperaquina y composiciones que las contienen. MX354453B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361804448P 2013-03-22 2013-03-22
PCT/EP2014/055747 WO2014147242A1 (en) 2013-03-22 2014-03-21 Piperaquine microcapsules and compositions containing them

Publications (2)

Publication Number Publication Date
MX2015013470A true MX2015013470A (es) 2016-06-02
MX354453B MX354453B (es) 2018-03-05

Family

ID=51789429

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015013470A MX354453B (es) 2013-03-22 2014-03-21 Microcapsulas de piperaquina y composiciones que las contienen.

Country Status (14)

Country Link
US (2) US20140322296A1 (es)
EP (1) EP2976069B1 (es)
JP (1) JP6345762B2 (es)
KR (1) KR20150133267A (es)
CN (1) CN105228597B (es)
AU (1) AU2014234258B2 (es)
BR (1) BR112015024359B1 (es)
CA (1) CA2907628C (es)
ES (1) ES2809254T3 (es)
MX (1) MX354453B (es)
PL (1) PL2976069T3 (es)
PT (1) PT2976069T (es)
SG (2) SG10201706609XA (es)
WO (1) WO2014147242A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104814931B (zh) * 2015-04-14 2017-12-26 华南农业大学 一种喹乙醇缓释颗粒及其制备方法和应用
US20180256515A1 (en) 2017-03-10 2018-09-13 Adare Pharmaceuticals, Inc. Oral amphetamine composition
CN114343230B (zh) * 2022-02-10 2023-05-12 湖北中烟工业有限责任公司 一种薄片添加剂、其制备方法及含有该薄片添加剂的烟草薄片

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7618651B2 (en) * 2004-06-24 2009-11-17 Idexx Laboratories Pharmaceutical compositions for drug delivery and methods of treating or preventing conditions using same
ES2615458T3 (es) * 2005-05-18 2017-06-07 Sun Pharmaceutical Industries Limited Formas de dosificación estables de antimaláricos de espiro y dispiro 1,2,4 trioxolano
TWI547282B (zh) * 2007-07-02 2016-09-01 愛戴爾製藥股份有限公司 樂命達之口服分解錠劑組合物
JP5309262B2 (ja) * 2009-12-02 2013-10-09 アプタリス ファーマ リミテッド フェキソフェナジン・マイクロカプセル及びそれを含む組成物

Also Published As

Publication number Publication date
EP2976069B1 (en) 2020-05-06
US20160045447A1 (en) 2016-02-18
PL2976069T3 (pl) 2020-10-19
BR112015024359B1 (pt) 2022-09-13
US20140322296A1 (en) 2014-10-30
SG11201507843TA (en) 2015-10-29
CN105228597B (zh) 2019-03-26
JP2016514720A (ja) 2016-05-23
CN105228597A (zh) 2016-01-06
WO2014147242A1 (en) 2014-09-25
AU2014234258A1 (en) 2015-10-08
BR112015024359A2 (pt) 2017-07-18
SG10201706609XA (en) 2017-09-28
CA2907628C (en) 2021-11-16
ES2809254T3 (es) 2021-03-03
US9668979B2 (en) 2017-06-06
PT2976069T (pt) 2020-08-05
CA2907628A1 (en) 2014-09-25
EP2976069A1 (en) 2016-01-27
MX354453B (es) 2018-03-05
KR20150133267A (ko) 2015-11-27
WO2014147242A8 (en) 2015-11-05
JP6345762B2 (ja) 2018-06-20
AU2014234258B2 (en) 2019-02-14

Similar Documents

Publication Publication Date Title
IL262581A (en) Production methods, preparations and medical applications of drugs containing cannabis for oral administration
WO2014147611A8 (en) Quinolines derivatives as novel anticancer agents
EP3398948A3 (en) 2,4,6,7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof
SA516380290B1 (ar) نواقل لفيروس مرتبط بالغدد لعلاج اضطرابات الاختزان في الجسيمات الحالة
WO2015077503A8 (en) Autotaxin inhibitor compounds
BR112015018087A8 (pt) composto, composição farmacêutica e uso
HK1243424A1 (zh) 4'-硫代核苷的新型化合物及其製備方法、藥物組合物和應用
WO2012174158A3 (en) Administration of benzodiazepine
GEP20196995B (en) Metabolites of n-(4-{[6,7-bis (methyloxy)quinolin-4-yl] oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide
WO2016077656A3 (en) Methods and compositions for inhibition of bromodomain and extraterminal proteins
WO2015015378A3 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
MY193740A (en) "substituted 2,4 diamino-quinoline as new anticancer agents"
EP3336100A4 (en) PEPTIDE WITH EFFECT FOR PREVENTING OR TREATING DISEASES OF THE CENTRAL NERVOUS SYSTEM AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING DISEASES OF THE CENTRAL NERVOUS SYSTEM THEREFOR AS AN ACTIVE SUBSTANCE
WO2015066302A3 (en) Compositions, methods of use, and methods of treatment
EP3352750A4 (en) Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient
MX2015013470A (es) Microcapsulas de piperaquina y composiciones que las contienen.
EP3311817A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF EYES DISEASES WITH IMATINIB AS AN ACTIVE SUBSTANCE
MX2017008983A (es) Composición farmaceútica de sulfonamida.
WO2015095659A3 (en) Indirubin solid dispersion composition
EP3638209A4 (en) NANOPARTICLE COMPOSITIONS, METHOD OF MANUFACTURING AND USE FOR DRUG DELIVERY
IL284132A (en) A pharmaceutical compound, a method for its preparation and its use as a medicinal substance
WO2014128728A3 (en) Solid forms of cabazitaxel and processes for preparation thereof
EA201400444A1 (ru) Производные 2-оксопиперидинила
PH12017500323A1 (en) P38 map kinase inhibiting indanyl urea compounds
WO2016109361A3 (en) 3-fluoro-benzonitrile inhibitors of 11-beta-hydroxylase

Legal Events

Date Code Title Description
FG Grant or registration